Exosect's platform technology receives Animal Health patent

22nd October 2014

Winchester, UK – Exosect Ltd, a leading provider of enabling technologies, has received notification from the UK Patent Office that it has been granted a patent for the control of arthropod infestations for Animal Health using its proprietary technology, Entostat, an electrostatic micro-powder, as a delivery platform for a range of active ingredients.

The present invention relates to methods of controlling arthropod infestation in both animal environments and on animals as in many cases of insect infestation, it is as important to treat animal housing, bedding, carpet etc. as the animal itself to control outbreaks and prevent their reoccurrence. The patent is relevant to livestock and companion animals where in both sectors, existing registered active ingredients are being re-formulated to reduce chemical loading, improve safety and overcome resistance.

Exosect’s CEO, Martin Brown comments, “We have an in-depth knowledge of formulating and targeting the delivery of a wide range of active ingredients using our electrostatic platform technology”. He continues, “this knowledge comes from over a decade of research and development more specifically in the Agriculture and Public Health sectors. This patent enables us to work more closely with partners in the Animal Health sector where there are the same pressures to reduce insecticide usage due to insect resistance and tightening regulation. These are key drivers for new formulation and application - innovations”.

                                                               - Ends -


Background information

The sales and use of ectoparasiticides for the control of arthropod parasites of domestic animals constitute approximately two thirds of the global animal health pesticide market. In a recent report by Markets and Markets , the global animal parasiticides market was valued at $6,509 million in 2013 and is expected to grow at a CAGR of 5.4% for the forecast period of 2013 to 2018. Within this sector, ectoparasiticides are used to treat or prevent external parasitic infestations such as fleas, ticks, mange mites, ear mites, lice, and sandflies.

Key market drivers include the spread of zoonotic diseases (transmitted between animals and humans by insect vectors e.g. Lymes disease), implementation of animal welfare acts in developed countries, the expansion of pet ownership and increasing demand for animal protein and animal-based food.

Market challenges include several factors such as restrictions on the use of parasiticides in food-producing animals in some countries, stringent regulations for approval of animal parasiticides, the cost and time of registering new products, insecticide resistance and product safety.

Notes to Editors

For further information please contact: Georgina Donovan at Exosect. 

Tel: 02380 603939 or email: georgina.donovan@exosect.com

Contact us: Send us an enquiry or call +44(0)845 199 5540